New Business Campaign Development
After successfully winning the new business for Somapacitan, a Novo Nordisk® once-weekly growth hormone medication, the next phase was to develop further creative thinking that would be used for testing in the marketplace . The brand name, Soqoya®, was applied to further tactical planning and development.
Campaign Development – 2nd Phase
With the addition of once-weekly Soqoya® to the AGHD therapy landscape, HCPs and their patients are looking at their therapeutic options in a whole new way. After all, with efficacy and tolerability comparable to daily GH therapy delivered with 6 fewer doses every week, it’s easy to see why things are looking up for everyone.
Every patient lives in a world that keeps spinning around, 7 days a week. That’s 7 days that should be filled with laughter, learning, layups, and love—not the distraction of daily dosing. Once-weekly Soqoya®. Because there’s so much more to life than AGHD therapy.
We’ve all grown up hearing the advice ‘carpe diem’ or ‘seize the day,’ urging us to enjoy life while we can. By changing the phrase to ‘Seize the week,’ Soqoya® turns this mantra into a bold, proprietary statement of empowerment. With just 1 dose a week, patients can embrace the potential of every single day with confidence.
